{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:20:15Z","timestamp":1768551615189,"version":"3.49.0"},"posted":{"date-parts":[[2021,9,14]]},"group-title":"Epidemiology","reference-count":65,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2021,9,14]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>Serosurveys are a key resource for measuring SARS-CoV-2 cumulative incidence. A growing body of evidence suggests that asymptomatic and mild infections (together making up over 95% of all infections) are associated with lower antibody titers than severe infections. Antibody levels also peak a few weeks after infection and decay gradually. We developed a statistical approach to produce adjusted estimates of seroprevalence from raw serosurvey results that account for these sources of spectrum bias. We incorporate data on antibody responses on multiple assays from a post-infection longitudinal cohort, along with epidemic time series to account for the timing of a serosurvey relative to how recently individuals may have been infected. We applied this method to produce adjusted seroprevalence estimates from five large-scale SARS-CoV-2 serosurveys across different settings and study designs. We identify substantial differences between reported and adjusted estimates of over two-fold in the results of some surveys, and provide a tool for practitioners to generate adjusted estimates with pre-set or custom parameter values. While unprecedented efforts have been launched to generate SARS-CoV-2 seroprevalence estimates over this past year, interpretation of results from these studies requires properly accounting for both population-level epidemiologic context and individual-level immune dynamics.<\/jats:p>","DOI":"10.1101\/2021.09.09.21263139","type":"posted-content","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T13:40:10Z","timestamp":1631626810000},"source":"Crossref","is-referenced-by-count":3,"title":["SARS-CoV-2 serology across scales: a framework for unbiased seroprevalence estimation incorporating antibody kinetics and epidemic recency"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5413-5507","authenticated-orcid":false,"given":"Saki","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0585-6230","authenticated-orcid":false,"given":"Michael J.","family":"Peluso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Hakim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keirstinne","family":"Turcios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owen","family":"Janson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0354-4076","authenticated-orcid":false,"given":"Isobel","family":"Routledge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Busch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Hoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viva","family":"Tai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Daniel","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9773-3256","authenticated-orcid":false,"given":"Jeffrey N.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6371-747X","authenticated-orcid":false,"given":"Steven G.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6684-0622","authenticated-orcid":false,"given":"Timothy J.","family":"Henrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0287-9111","authenticated-orcid":false,"given":"Bryan","family":"Greenhouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6784-1021","authenticated-orcid":false,"given":"Isabel","family":"Rodr\u00edguez-Barraquer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2021091603150595000_2021.09.09.21263139v1.1","doi-asserted-by":"crossref","unstructured":"Arora RK , Joseph A , Van Wyk J , et al. SeroTracker: a global SARS-CoV-2 seroprevalence dashboard. Lancet Infect. Dis. [electronic article]. 2020;(http:\/\/dx.doi.org\/10.1016\/S1473-3099(20)30631-9)","DOI":"10.1016\/S1473-3099(20)30631-9"},{"key":"2021091603150595000_2021.09.09.21263139v1.2","doi-asserted-by":"crossref","unstructured":"Chen X , Chen Z , Azman AS , et al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. Lancet Glob Health [electronic article]. 2021;(http:\/\/dx.doi.org\/10.1016\/S2214-109X(21)00026-7)","DOI":"10.1016\/S2214-109X(21)00026-7"},{"issue":"1","key":"2021091603150595000_2021.09.09.21263139v1.3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/oxfordjournals.aje.a112510","article-title":"Estimating prevalence from the results of a screening test","volume":"107","year":"1978","journal-title":"Am. J. Epidemiol. [electronic article]"},{"issue":"5","key":"2021091603150595000_2021.09.09.21263139v1.4","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/rssc.12435","article-title":"Bayesian analysis of tests with unknown specificity and sensitivity","volume":"69","year":"2020","journal-title":"J. R. Stat. Soc. C [electronic article]"},{"key":"2021091603150595000_2021.09.09.21263139v1.5","doi-asserted-by":"crossref","unstructured":"Larremore DB , Fosdick BK , Zhang S , et al. Jointly modeling prevalence, sensitivity and specificity for optimal sample allocation. bioRxiv. :2020.05.23.112649. (http:\/\/dx.doi.org\/10.1101\/2020.05.23.112649). (Accessed October 12, 2020)","DOI":"10.1101\/2020.05.23.112649"},{"issue":"9","key":"2021091603150595000_2021.09.09.21263139v1.6","doi-asserted-by":"crossref","first-page":"e1008796","DOI":"10.1371\/journal.ppat.1008796","article-title":"A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients","volume":"16","year":"2020","journal-title":"PLoS Pathog. [electronic article]"},{"issue":"12","key":"2021091603150595000_2021.09.09.21263139v1.7","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.3201\/eid2612.203334","article-title":"Antibody Profiles According to Mild or Severe SARS-CoV-2 Infection, Atlanta, Georgia, USA, 2020","volume":"26","year":"2020","journal-title":"Emerg. Infect. Dis. [electronic article]"},{"key":"2021091603150595000_2021.09.09.21263139v1.8","unstructured":"Iyer AS , Jones FK , Nodoushani A , et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol [electronic article]. 2020;5(5). (http:\/\/dx.doi.org\/10.1126\/sciimmunol.abe0367)"},{"key":"2021091603150595000_2021.09.09.21263139v1.9","doi-asserted-by":"crossref","unstructured":"Ibarrondo FJ , Fulcher JA , Goodman-Meza D , et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N. Engl. J. Med. [electronic article]. 2020;(http:\/\/dx.doi.org\/10.1056\/NEJMc2025179)","DOI":"10.1056\/NEJMc2025179"},{"key":"2021091603150595000_2021.09.09.21263139v1.10","doi-asserted-by":"crossref","unstructured":"Takahashi S , Greenhouse B , Rodr\u00edguez-Barraquer I. Are Seroprevalence Estimates for Severe Acute Respiratory Syndrome Coronavirus 2 Biased? J. Infect. Dis. [electronic article]. 2020;(http:\/\/dx.doi.org\/10.1093\/infdis\/jiaa523)","DOI":"10.1093\/infdis\/jiaa523"},{"key":"2021091603150595000_2021.09.09.21263139v1.11","doi-asserted-by":"crossref","unstructured":"Chen S , Flegg JA , White LJ , et al. Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys. bioRxiv. 2021;(http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.01.08.21249432)","DOI":"10.1101\/2021.01.08.21249432"},{"key":"2021091603150595000_2021.09.09.21263139v1.12","doi-asserted-by":"crossref","unstructured":"Shioda K , Lau MS , Kraay AN , et al. Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies. medRxiv [electronic article]. 2020;(http:\/\/dx.doi.org\/10.1101\/2020.11.13.20231266)","DOI":"10.1101\/2020.11.13.20231266"},{"key":"2021091603150595000_2021.09.09.21263139v1.13","doi-asserted-by":"crossref","unstructured":"Perez-Saez J , Zaballa M-E , Yerly S , et al. Persistence and detection of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance. bioRxiv. 2021;(http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.03.16.21253710)","DOI":"10.1101\/2021.03.16.21253710"},{"key":"2021091603150595000_2021.09.09.21263139v1.14","unstructured":"Report 34 - COVID-19 Infection Fatality Ratio Estimates from Seroprevalence. (https:\/\/www.imperial.ac.uk\/mrc-global-infectious-disease-analysis\/covid-19\/report-34-ifr\/). (Accessed April 6, 2021)"},{"key":"2021091603150595000_2021.09.09.21263139v1.15","unstructured":"Buss LF , Prete CA Jr , Abrahim CMM , et al. COVID-19 herd immunity in the Brazilian Amazon. medRxiv. 2020;(http:\/\/dx.doi.org\/10.1101\/2020.09.16.20194787)"},{"issue":"6500","key":"2021091603150595000_2021.09.09.21263139v1.16","first-page":"208","article-title":"Estimating the burden of SARS-CoV-2 in France","volume":"369","year":"2020","journal-title":"Science [electronic article]"},{"key":"2021091603150595000_2021.09.09.21263139v1.17","doi-asserted-by":"crossref","unstructured":"Peluso MJ , Takahashi S , Hakim J , et al. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Sci Adv [electronic article]. 2021;7(7). (http:\/\/dx.doi.org\/10.1126\/sciadv.abh3409)","DOI":"10.1126\/sciadv.abh3409"},{"key":"2021091603150595000_2021.09.09.21263139v1.18","doi-asserted-by":"crossref","unstructured":"Peluso MJ , Deitchman AN , Torres L , et al. Long-Term SARS-CoV-2-Specific Immune and Inflammatory Responses Across a Clinically Diverse Cohort of Individuals Recovering from COVID-19. medRxiv [electronic article]. 2021;(http:\/\/dx.doi.org\/10.1101\/2021.02.26.21252308)","DOI":"10.1101\/2021.02.26.21252308"},{"key":"2021091603150595000_2021.09.09.21263139v1.19","unstructured":"Peluso MJ , Kelly JD , Lu S , et al. Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection\/COVID-19. medRxiv [electronic article]. 2021;(http:\/\/dx.doi.org\/10.1101\/2021.03.11.21252311)"},{"issue":"6","key":"2021091603150595000_2021.09.09.21263139v1.20","first-page":"845","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","year":"2020","journal-title":"Nat. Med. [electronic article]"},{"issue":"6","key":"2021091603150595000_2021.09.09.21263139v1.21","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1473-3099(20)30243-7","article-title":"Estimates of the severity of coronavirus disease 2019: a model-based analysis","volume":"20","year":"2020","journal-title":"Lancet Infect. Dis. [electronic article]"},{"issue":"20","key":"2021091603150595000_2021.09.09.21263139v1.22","first-page":"2240","article-title":"Biomarker dynamics: estimating infection rates from serological data","volume":"31","year":"2012","journal-title":"Stat. Med. [electronic article]"},{"key":"2021091603150595000_2021.09.09.21263139v1.23","unstructured":"Primi risultati dell\u2019indagine di sieroprevalenza sul SARS-CoV-2. 2020;(https:\/\/www.istat.it\/it\/archivio\/246156). (Accessed October 12, 2020)"},{"key":"2021091603150595000_2021.09.09.21263139v1.24","unstructured":"ENE-COVID. ESTUDIO ENE-COVID: INFORME FINAL - ESTUDIO NACIONAL DE SERO-EPIDEMIOLOG\u00cdA DE LA INFECCI\u00d3N POR SARS-COV-2 EN ESPA\u00d1A. 2020.(https:\/\/portalcne.isciii.es\/enecovid19\/informes\/informe_final.pdf)"},{"issue":"10250","key":"2021091603150595000_2021.09.09.21263139v1.25","first-page":"535","article-title":"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study","volume":"396","year":"2020","journal-title":"Lancet [electronic article]"},{"key":"2021091603150595000_2021.09.09.21263139v1.26","first-page":"m4509","article-title":"Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study","volume":"371","year":"2020","journal-title":"BMJ [electronic article]"},{"key":"2021091603150595000_2021.09.09.21263139v1.27","doi-asserted-by":"crossref","unstructured":"Bajema KL , Wiegand RE , Cuffe K , et al. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. JAMA Intern. Med. [electronic article]. 2020;(http:\/\/dx.doi.org\/10.1001\/jamainternmed.2020.7976)","DOI":"10.1001\/jamainternmed.2020.7976"},{"issue":"6526","key":"2021091603150595000_2021.09.09.21263139v1.28","first-page":"288","article-title":"Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic","volume":"371","year":"2021","journal-title":"Science [electronic article]"},{"issue":"10273","key":"2021091603150595000_2021.09.09.21263139v1.29","first-page":"452","article-title":"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence","volume":"397","year":"2021","journal-title":"Lancet [electronic article]"},{"key":"2021091603150595000_2021.09.09.21263139v1.30","unstructured":"Ministry of Health, Labour and Welfare. \u6297\u4f53\u4fdd\u6709\u8abf\u67fb(\u7b2c2\u56de)\u901f\u5831\u7d50\u679c. (https:\/\/www.mhlw.go.jp\/content\/000734482.pdf)"},{"key":"2021091603150595000_2021.09.09.21263139v1.31","unstructured":"The Royal Society. Reproduction number (R) and growth rate (r) of the COVID-19 epidemic in the UK. (https:\/\/royalsociety.org\/-\/media\/policy\/projects\/set-c\/set-covid-19-R-estimates.pdf)"},{"key":"2021091603150595000_2021.09.09.21263139v1.32","unstructured":"Estimate Real-Time Case Counts and Time-Varying Epidemiological Parameters. (https:\/\/epiforecasts.io\/EpiNow2\/index.html). (Accessed April 1, 2021)"},{"issue":"1","key":"2021091603150595000_2021.09.09.21263139v1.33","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1742-4682-4-20","article-title":"Time variations in the transmissibility of pandemic influenza in Prussia, Germany, from 1918\u201319","volume":"4","year":"2007","journal-title":"Theor. Biol. Med. Model. [electronic article]"},{"issue":"8","key":"2021091603150595000_2021.09.09.21263139v1.34","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S1473-3099(20)30287-5","article-title":"Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study","volume":"20","year":"2020","journal-title":"Lancet Infect. Dis. [electronic article]"},{"key":"2021091603150595000_2021.09.09.21263139v1.35","doi-asserted-by":"crossref","unstructured":"Linton NM , Kobayashi T , Yang Y , et al. Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data. J. Clin. Med. Res. [electronic article]. 2020;9(9). (http:\/\/dx.doi.org\/10.3390\/jcm9020538)","DOI":"10.1101\/2020.01.26.20018754"},{"issue":"1-2","key":"2021091603150595000_2021.09.09.21263139v1.36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0167-5877(00)00119-7","article-title":"Conditional dependence between tests affects the diagnosis and surveillance of animal diseases","volume":"45","year":"2000","journal-title":"Prev. Vet. Med. [electronic article]"},{"key":"2021091603150595000_2021.09.09.21263139v1.37","doi-asserted-by":"crossref","unstructured":"Appa A , Takahashi S , Rodriguez-Barraquer I , et al. Universal PCR and antibody testing demonstrate little to no transmission of SARS-CoV-2 in a rural community. medRxiv [electronic article]. 2020;(http:\/\/dx.doi.org\/10.1101\/2020.08.15.20175786)","DOI":"10.1101\/2020.08.15.20175786"},{"key":"2021091603150595000_2021.09.09.21263139v1.38","unstructured":"Espa\u00f1a EN. ESTUDIOENE-COVID:CUARTARONDA. (https:\/\/portalcne.isciii.es\/enecovid19\/informes\/informe_cuarta_ronda.pdf). (Accessed April 5, 2021)"},{"key":"2021091603150595000_2021.09.09.21263139v1.39","unstructured":"CDC. COVID Data Tracker. Nationwide Commercial Laboratory Seroprevalence Survey. (https:\/\/covid.cdc.gov\/covid-data-tracker\/#national-lab). (Accessed April 2, 2021)"},{"key":"2021091603150595000_2021.09.09.21263139v1.40","unstructured":"\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u306b\u95a2\u9023\u3057\u305f\u80ba\u708e\u306e\u60a3\u8005\u306e\u767a\u751f\u306b\u3064\u3044\u3066(1\u4f8b\u76ee). (https:\/\/www.mhlw.go.jp\/stf\/newpage_08906.html). (Accessed June 1, 2021)"},{"key":"2021091603150595000_2021.09.09.21263139v1.41","unstructured":"Cheng C , Zhou H , Weiss JC , et al. Unpacking the Drop in COVID-19 Case Fatality Rates: A Study of National and Florida Line-Level Data. arXiv [stat.AP]. 2020;(http:\/\/arxiv.org\/abs\/2012.04825)"},{"key":"2021091603150595000_2021.09.09.21263139v1.42","unstructured":"Ainsworth M , Andersson M , Auckland K , et al. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect. Dis. [electronic article]. 2020;(http:\/\/www.sciencedirect.com\/science\/article\/pii\/S1473309920306344)"},{"key":"2021091603150595000_2021.09.09.21263139v1.43","doi-asserted-by":"crossref","unstructured":"Di Germanio C , Simmons G , Kelly K , et al. SARS-CoV-2 Antibody persistence in COVID-19 convalescent plasma donors. medRxiv [electronic article]. 2021;2021.03.24.21254260. (https:\/\/www.medrxiv.org\/content\/10.1101\/2021.03.24.21254260v1.abstract). (Accessed April 5, 2021)","DOI":"10.1101\/2021.03.24.21254260"},{"issue":"3","key":"2021091603150595000_2021.09.09.21263139v1.44","first-page":"389","article-title":"Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients","volume":"223","year":"2021","journal-title":"J. Infect. Dis. [electronic article]"},{"issue":"3","key":"2021091603150595000_2021.09.09.21263139v1.45","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2214-109X(20)30544-1","article-title":"SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey","volume":"9","year":"2021","journal-title":"Lancet Glob Health [electronic article]"},{"issue":"1","key":"2021091603150595000_2021.09.09.21263139v1.46","first-page":"4704","article-title":"A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity","volume":"11","year":"2020","journal-title":"Nat. Commun. [electronic article]"},{"issue":"12","key":"2021091603150595000_2021.09.09.21263139v1.47","doi-asserted-by":"crossref","first-page":"e1008409","DOI":"10.1371\/journal.pcbi.1008409","article-title":"Practical considerations for measuring the effective reproductive number, Rt","volume":"16","year":"2020","journal-title":"PLoS Comput. Biol. [electronic article]"},{"issue":"8","key":"2021091603150595000_2021.09.09.21263139v1.48","first-page":"1205","article-title":"Age-dependent effects in the transmission and control of COVID-19 epidemics","volume":"26","year":"2020","journal-title":"Nat. Med. [electronic article]"},{"key":"2021091603150595000_2021.09.09.21263139v1.49","doi-asserted-by":"crossref","unstructured":"Meyerowitz EA , Richterman A , Bogoch II , et al. Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2. Lancet Infect. Dis. [electronic article]. 2020;(http:\/\/dx.doi.org\/10.1016\/S1473-3099(20)30837-9)","DOI":"10.2139\/ssrn.3670755"},{"key":"2021091603150595000_2021.09.09.21263139v1.50","doi-asserted-by":"crossref","unstructured":"Takahashi T , Wong P , Ellingson M , et al. Sex differences in immune responses to SARS-CoV-2 that underlie disease outcomes. medRxiv [electronic article]. 2020;(http:\/\/dx.doi.org\/10.1101\/2020.06.06.20123414)","DOI":"10.1101\/2020.06.06.20123414"},{"key":"2021091603150595000_2021.09.09.21263139v1.51","doi-asserted-by":"crossref","unstructured":"Klein SL , Pekosz A , Park H-S , et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J. Clin. Invest. [electronic article]. 2020;(http:\/\/dx.doi.org\/10.1172\/JCI142004)","DOI":"10.1101\/2020.06.26.20139063"},{"key":"2021091603150595000_2021.09.09.21263139v1.52","unstructured":"ReportPrimiRisultatiIndagineSiero.pdf. (https:\/\/www.istat.it\/it\/files\/\/2020\/08\/ReportPrimiRisultatiIndagineSiero.pdf)"},{"key":"2021091603150595000_2021.09.09.21263139v1.53","unstructured":"EpiCentro. [No title]. (https:\/\/www.epicentro.iss.it\/coronavirus\/sars-cov-2-sorveglianza-dati). (Accessed April 6, 2021)"},{"key":"2021091603150595000_2021.09.09.21263139v1.54","unstructured":"Dati COVID-19 Italia. Github; (Accessed April 6, 2021).(https:\/\/github.com\/pcm-dpc\/COVID-19). (Accessed April 6, 2021)"},{"key":"2021091603150595000_2021.09.09.21263139v1.55","unstructured":"Centro Nacional de Epidemiolog\u00eda. COVID-19 en Espa\u00f1a. (https:\/\/cnecovid.isciii.es\/). (Accessed April 1, 2021)"},{"key":"2021091603150595000_2021.09.09.21263139v1.56","unstructured":"The New York Times. Coronavirus (Covid-19) Data in the United States. (https:\/\/github.com\/nytimes\/covid-19-data). (Accessed April 1, 2021)"},{"key":"2021091603150595000_2021.09.09.21263139v1.57","unstructured":"do Amazonas-FVS\/AM F de V em S. Transpar\u00eancia COVID-19. S\u00e9ries Temporais COVID-19 no Amazonas. (http:\/\/www.fvs.am.gov.br\/indicadorSalaSituacao_view\/69\/2). (Accessed April 1, 2021)"},{"key":"2021091603150595000_2021.09.09.21263139v1.58","unstructured":"Tableau Public. (https:\/\/public.tableau.com\/profile\/astec.sass#!\/vizhome\/Subnotificao\/HospMun). (Accessed April 6, 2021)"},{"key":"2021091603150595000_2021.09.09.21263139v1.59","unstructured":"Open data. (https:\/\/www.mhlw.go.jp\/stf\/covid-19\/open-data_english.html). (Accessed April 6, 2021)"},{"key":"2021091603150595000_2021.09.09.21263139v1.60","unstructured":"\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9(COVID-19)\u611f\u67d3\u75c7\u306e\u5bfe\u5fdc\u306b\u3064\u3044\u3066|\u5185\u95a3\u5b98\u623f\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7\u5bfe\u7b56\u63a8\u9032\u5ba4. (https:\/\/corona.go.jp\/dashboard\/). (Accessed April 6, 2021)"},{"key":"2021091603150595000_2021.09.09.21263139v1.61","unstructured":"\u6771\u4eac\u90fd..\u6771\u4eac\u90fd.\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7.\u5bfe\u7b56\u30b5\u30a4\u30c8. (https:\/\/stopcovid19.metro.tokyo.lg.jp\/). (Accessed April 6, 2021)"},{"key":"2021091603150595000_2021.09.09.21263139v1.62","unstructured":"CODEforOSAKA. \u5927\u962a\u5e9c.\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7\u5bfe\u7b56\u30b5\u30a4\u30c8. (https:\/\/covid19-osaka.info\/). (Accessed April 6, 2021)"},{"key":"2021091603150595000_2021.09.09.21263139v1.63","unstructured":"\u770c\u5185\u306e\u767a\u751f\u72b6\u6cc1. (https:\/\/www.pref.miyagi.jp\/site\/covid-19\/02.html). (Accessed April 6, 2021)"},{"key":"2021091603150595000_2021.09.09.21263139v1.64","unstructured":"\u611b\u77e5\u770c. \u611b\u77e5\u770c.\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7\u5bfe\u7b56\u30b5\u30a4\u30c8. (https:\/\/stopcovid19.code4.nagoya\/). (Accessed April 6, 2021)"},{"key":"2021091603150595000_2021.09.09.21263139v1.65","unstructured":"\u798f\u5ca1\u770c.\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7.\u967d\u6027\u8005\u767a\u8868\u60c5\u5831.-\u81ea\u6cbb\u4f53\u30aa\u30fc\u30d7\u30f3\u30c7\u30fc\u30bf\u306eCKAN. (https:\/\/ckan.open-governmentdata.org\/dataset\/401000_pref_fukuoka_covid19_patients). (Accessed April 6, 2021)"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2021.09.09.21263139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:24:24Z","timestamp":1768487064000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.09.09.21263139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":65,"URL":"https:\/\/doi.org\/10.1101\/2021.09.09.21263139","relation":{},"subject":[],"published":{"date-parts":[[2021,9,14]]},"subtype":"preprint"}}